APM (Aptorum Group) Issuance of Debt : $5.50 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Issuance of Debt?

Aptorum Group's Issuance of Debt for the six months ended in Dec. 2023 was $3.00 Mil.

Aptorum Group's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 was $5.50 Mil.

Aptorum Group Issuance of Debt Historical Data

The historical data trend for Aptorum Group's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Issuance of Debt Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Issuance of Debt

Get a 7-Day Free Trial

6.33

1.00

3.50

6.50

5.50

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Issuance of Debt	Get a 7-Day Free Trial								-	3.00	3.50	2.50	3.00

Aptorum Group Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.50 Mil.

Aptorum Group Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptorum Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.